Intercellular transfer of exosomal wild type EGFR triggers osimertinib resistance in non-small cell lung cancer.

ABSTRACT:

Background

Epidermal growth factor receptor (EGFR)-mutated lung cancer constitutes a major subgroup of non-small cell lung cancer (NSCLC) and osimertinib is administrated as first-line treatment. However, most patients with osimertinib treatment eventually relapse within one year. The underlying mechanisms of osimertinib resistance remain largely unexplored.

Methods

Exosomes isolation was performed by differential centrifugation. Co-culture assays were conducted to explore the alteration of drug sensitivity by cell viability and apoptosis assays. Immunofluorescence and flow cytometry were performed to visualize the formation or absorption of exosomes. Exosomes secretion was measured by Nanoparticle Tracking Analysis or ELISA. The xenograft tumor model in mice was established

SUBMITTER: Wu S 

PROVIDER: S-EPMC7812728 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature